5th International Metabolic Diseases Drug Development Summit to Reveal Promising Clinical Updates From Top-Tier Big Pharma Companies July 24-25, 2006 Del Mar, CA
Posted on: Thursday, 4 May 2006, 12:03 CDT
DEL MAR, Calif., May 4 /PRNewswire/ -- The 5th International Metabolic Diseases Drug Discovery and Development World Summit, which will feature the latest industry and academic advances by the leaders in the fields of diabetes and obesity -- will convene July 24-25, 2006 in Del Mar, CA, announces Strategic Research Institute. Year after year, this meeting features perhaps the finest group of diabetes and obesity experts from around the world to address the most promising avenues of investigation.
This conference is considered to be the premier conference for diabetes and obesity researchers, as the field still continues to expand and as the number of approved products increases yearly. This conference also offers an opportunity to learn about emerging concepts on the Metabolic Syndrome including the latest on harmonization of its definition, "root cause(s)," pathobiologic mechanisms, new molecular targets and new areas for discovery including CNS lipid pathways, adipose tissue inflammation, and the contribution of stress-response pathways in the development of the Metabolic Syndrome.
The first's day general session includes breakthrough updates on Byetta(TM), Arxxant(TM), Januvia(TM), ABT-279, APD356, KB2115, and many more. Academic keynote presentations include:
Metabolic Syndrome: Significance and Drug Discovery Approaches Scott M. Grundy, M.D., Ph.D., UNIVERSITY OT TEXAS SOUTHWESTERN Restoration of Hypothalamic Lipid Sensing Normalizes Energy and Glucose Homeostasis in Overfed Rats Luciano Rossetti, M.D., ALBERT EINSTEIN COLLEGE OF MEDICINE Molecular and Cellular Pathways that Link Inflammation and Type II Diabetes Michael Karin, Ph.D., UNIVERSITY OF CALIFORNIA - SAN DIEGO
To receive the full agenda in PDF and/or request information, please contact Ed Drilon of Strategic Research Institute at edrilon@srinstitute.com or 212-967-0095, x233 (please include name, corporate affiliation, mailing address, and fax number and specify what you are interested in).
For more information on sponsorship & exhibition opportunities, please contact Sandra Shlayanat sshlayan@srinstitute.com or at 212-967-0095 x239.
To become a media partner, please contact Cheryl Kahan-Radhuber at ckahan-radhuber@srinstitute.com.
Strategic Research Institute
CONTACT: Ed Drilon, edrilon@srinstitute.com, +1-212-967-0095 x233, orSandra Shlayanat, sshlayan@srinstitute.com, +1-212-967-0095 x239, or CherylKahan-Radhuber, ckahan-radhuber@srinstitute.com, all of Strategic ResearchInstitute
Web site: http://www.srinstitute.com/
Source: PRNewswire
Related Articles
- Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
- Scott A. Summers, Ph.D. Of the University of Utah and Ira Goldberg, M.D. Of Columbia University to Deliver Opening Keynotes at Largest Industry-Focused Diabetes & Obesity Summit, July 16-17, 2007 in San Diego, CA
- Future Therapies for Viral Hepatitis to Be Discussed at the 3rd Annual Viral Hepatitis World Summit, March 12-13, Boston
- Metabolic's Obesity Trial Update: First 100 Subjects Complete the Phase 2B Trial of AOD9604
- Analysts Predict Robust Growth for Stem Cells & Regenerative Medicine
- New Treatments for Cancer and Age-Related Macular Degeneration on the Horizon
- Scott Grundy of U. Texas Southwestern and Luciano Rossetti of Albert Einstein College to Deliver Opening Keynotes at Largest Industry-Focused Diabetes & Obesity Summit, July 24-25, 2006 Del Mar, CA
- Amgen and Biovitrum Expand Existing License Agreement for Innovative Treatment of Type 2 Diabetes and Other Metabolic Disorders
- Biovitrum and Santhera Sign an Exclusive License and Collaboration Agreement for the Development of DPP-IV Inhibitors for the Treatment of Type 2 Diabetes and Other Metabolic Diseases
- Heart Disease Expert Calls for Aggressive Cholesterol-Lowering Therapy for Patients With Diabetes and the Metabolic Syndrome
 |
 |
User Comments (0)
RSS Feeds